|
1
|
Shimada H: Revisiting radiation therapy
for esophageal cancer. Esophagus. 17(99)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yang B, Liu Y, Li L, Deng H and Xian L:
MicroRNA-200a promotes esophageal squamous cell carcinoma cell
proliferation, migration and invasion through extensive target
genes. Mol Med Rep. 21:2073–2084. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fernandes E, Sores J, Cotton S, Peixoto A,
Ferreira D, Freitas R, Reis CA, Santos LL and Ferreira JA:
Esophageal, gastric and colorectal cancers: Looking beyond
classical serological biomarkers towards glycoproteomics-assisted
precision oncology. Theranostics. 31:4903–4928. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shimada H, Takeda A, Arima M, Okazumi S,
Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, et
al: Serum p53 antibody is a useful tumor marker in superficial
esophageal squamous cell carcinoma. Cancer. 89:1677–1683.
2000.PubMed/NCBI
|
|
5
|
Kochi R, Yajima S, Nanami T, Suzuki T,
Oshima Y, Tokura N, Takatsuka J, Funahashi K, Tochigi N and Shimada
H: Five-year postsurgical monitoring of serum p53 antibody for
locally advanced esophageal squamous cell carcinoma. Clin J
Gastroenterol. 11:278–281. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Suzuki T, Yajima S, Ishioka N, Nanami T,
Oshima Y, Washizawa N, Funahashi K, Otsuka S, Nemoto T and Shimada
H: Prognostic significance of high serum p53 antibody titers in
patients with esophageal squamous cell carcinoma. Esophagus.
15:294–300. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ito M, Yajima S, Suzuki T, Oshima Y,
Nanami T, Sumazaki M, Shiratori F, Funahashi K, Tochigi N and
Shimada H: High serum PD-L1 level is a poor prognostic biomarker in
surgically treated esophageal cancer. Cancer Med. 9:1321–1327.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ito M, Oshima Y, Yajima S, Suzuki T,
Nanami T, Shiratori F, Funahashi K, Nemoto T and Shimada H: Is high
serum programmed death ligand 1 level a risk factor for poor
survival in patients with gastric cancer? Ann Gastroenterol Surg.
2:313–318. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ito M, Oshima Y, Yajima S, Suzuki T,
Nanami T, Shiratori F, Funahashi K and Shimada H: Diagnostic impact
of high serum midkine level in patients with gastric cancer. Ann
Gastroenterol Surg. 3:195–201. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Oshima Y, Shimada H, Yajima S, Nanami T,
Matsushita K, Nomura F, Kainuma O, Takiguchi N, Soda H, Ueda T, et
al: NY-ESO-1 autoantibody as a tumor-specific biomarker for
esophageal cancer: Screening in 1969 patients with various cancers.
J Gastroenterol. 51:30–34. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sahin U, Tureci O, Schmitt H, Cochlovius
B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I and
Pfreundschuh M: Human neoplasms elicit multiple specific immune
responses in the autologous host. Proc Natl Acad Sci USA.
92:11810–11813. 1995.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cancer Immunome Database: Available from:
http://www2.licr.org/CancerImmunomeDB/.
|
|
13
|
Nakashima K, Shimada H, Ochiai T,
Kuboshima M, Kuroiwa N, Okazumi S, Matsubara H, Nomura F, Takiguchi
M and Hiwasa T: Serological identification of TROP2 by recombinant
cDNA expression cloning using sera of patients with esophageal
squamous cell carcinoma. Int J Cancer. 112:1029–1035.
2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kuboshima M, Shimada H, Liu TL, Nakashima
K, Nomura F, Takiguchi M, Hiwasa T and Ochiai T: Identification of
a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell
carcinoma. Int J Oncol. 28:463–468. 2006.PubMed/NCBI
|
|
15
|
Kuboshima M, Shimada H, Liu TL, Nomura F,
Takiguchi M, Hiwasa T and Ochiai T: Presence of serum tripartite
motif-containing 21 antibodies in patients with esophageal squamous
cell carcinoma. Cancer Sci. 97:380–386. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shimada H, Kuboshima M, Shiratori T,
Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T and
Hiwasa T: Serum anti-myomegalin antibodies in patients with
esophageal squamous cell carcinoma. Int J Oncol. 30:97–103.
2007.PubMed/NCBI
|
|
17
|
Shimada H, Shiratori T, Yasuraoka M,
Kagaya A, Kuboshima M, Nomura F, Takiguchi M, Ochiai T, Matsubara H
and Hiwasa T: Identification of Makorin 1 as a novel SEREX antigen
of esophageal squamous cell carcinoma. BMC Cancer.
9(232)2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kagaya A, Shimada H, Shiratori T,
Kuboshima M, Nakashima-Fujita K, Yasuraoka M, Nishimori T, Kurei S,
Hachiya T, Murakami A, et al: Identification of a novel SEREX
antigen family, ECSA, in esophageal squamous cell carcinoma.
Proteome Sci. 9(31)2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Japan Esophageal Society. Japanese
Classification of Esophageal Cancer, 11th Edition: Part I.
Esophagus. 14:1–36. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Japanese Gastric Cancer Association.
Japanese classification of gastric carcinoma: 3rd English edition
Japanese Gastric Cancer Association. Gastric Cancer. 14:101–112.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Japanese Society for Cancer of the Colon
and Rectum. Japanese Classification of Colorectal, Appendiceal, and
Anal Carcinoma: The 3d English Edition [Secondary Publication]. J
Anus Rectum Colon. 3:175–195. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shimada H, Kagaya A, Shiratori T, Nomura
F, Takiguchi M, Matsubara H and Hiwasa T: Detection of anti-CUEC-23
antibodies in serum of patients with esophageal squamous cell
carcinoma: A possible new serum marker for esophageal cancer. J
Gastroenterol. 44:691–696. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Matsutani T, Hiwasa T, Takiguchi M, Oide
T, Kunimatsu M, Saeki N and Iwadate Y: Autologous antibody to
Src-homology 3-domain GRB2-like 1 specifically increases in the
sera of patients with low-grade gliomas. J Exp Clin Cancer Res.
31(85)2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Machida T, Kubota M, Kobayashi E, Iwadate
Y, Saeki N, Yamaura A, Nomura F, Takiguchi M and Hiwasa T:
Identification of stroke-associated-antigens via screening of
recombinant proteins from the human expression cDNA library
(SEREX). J Transl Med. 13(71)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yoshida Y, Wang H, Hiwasa T, Machida T,
Kobayashi E, Mine S, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H,
et al: Elevation of autoantibody level against PDCD11 in patients
with transient ischemic attack. Oncotarget. 9:8836–8848.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang H, Zhang XM, Tomiyoshi G, Nakamura R,
Shinmen N, Kuroda H, Kimura R, Mine S, Kamitsukasa I, Wada T, et
al: Association of serum levels of antibodies against MMP1, CBX1,
and CBX5 with transient ischemic attack and cerebral infarction.
Oncotarget. 9:5600–5613. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kobayashi S, Hiwasa T, Ishige T,
Rahmutulla B, Kano M, Hoshino T, Minamoto T, Shimada H, Nomura F,
Matsubara H and Matsushita K: Anti-FIRΔexon2, a splicing variant
form of PUF60, autoantibody is detected in the sera of esophageal
squamous cell carcinoma. Cancer Sci. 110:2004–2013. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hiwasa T, Machida T, Zhang XM, Kimura R,
Wang H, Iwase K, Ashino H, Taira A, Arita E, Mine S, et al:
Elevated levels of autoantibodies against ATP2B4 and BMP-1 in sera
of patients with atherosclerosis-related diseases. Immunome Res.
11(97)2015.
|
|
29
|
Hiwasa T, Tomiyoshi G, Nakamura R, Shinmen
N, Kuroda H, Kunimatsu M, Mine S, Machida T, Sato E, Takemoto M, et
al: Serum SH3BP5-specific antibody level is a biomarker of
atherosclerosis. Immunome Res. 13(132)2017.
|
|
30
|
Shimada H, Ochiai T and Nomura F: Japan
p53 Antibody Research Group. Titration of serum p53 antibodies in
1,085 patients with various types of malignant tumors: A
multiinstitutional analysis by the Japan p53 Antibody Research
Group. Cancer. 97:682–689. 2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shimada H, Nabeya Y, Okazumi S, Matsubara
H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H and Ochiai T:
Prediction of survival with squamous cell carcinoma antigen in
patients with resectable esophageal squamous cell carcinoma.
Surgery. 133:486–494. 2003.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Castets F, Bartoli M, Barnier JV, Baillat
G, Salin P, Moqrich A, Bourgeois JP, Denizot F, Rougon G, Calothy G
and Monneron A: A novel calmodulin-binding protein, belonging to
the WD-repeat family, is localized in dendrites of a subset of CNS
neurons. J Cell Biol. 134:1051–1062. 1996.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Muro Y, Chan EK, Landberg G and Tan EM: A
cell-cycle nuclear autoantigen containing WD-40 motifs expressed
mainly in S and G2 phase cells. Biochem Biophys Res Commun.
207:1029–1037. 1995.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Castets F, Rakitina T, Gaillard S, Moqrich
A, Mattei MG and Monneron A: Zinedin, SG2NA, and striatin are
calmodulin-binding, WD repeat proteins principally expressed in the
brain. J Biol Chem. 275:19970–19977. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Janssens V and Goris J: Protein
phosphatase 2A: A highly regulated family of serine/threonine
phosphatases implicated in cell growth and signalling. Biochem J.
353(417)2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hoof CV and Goris J: Phosphatases in
apoptosis: To be or not to be, PP2A is in the heart of the
question. Biochim Biophys Acta. 1640:97–104. 2003.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wong M, Hyodo T, Asano E, Funasaka K,
Miyahara R, Hirooka Y, Goto H, Hamaguchi M and Senga T: Silencing
of STRN4 suppresses the malignant characteristics of cancer cells.
Cancer Sci. 105:1526–1532. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang Z, Li Y, Cao J, Zhang W, Wang Q,
Zhang Z, Gao Z, Ye Y, Jiang K and Wang S: MicroRNA profile
identifies miR-6165 could suppress gastric cancer migration and
invasion by targeting STRN4. Onco Targets Ther. 13:1859–1869.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jiang F, Zheng Q, Chang L, Li X, Wang X
and Gu X: Pro-oncogene pokemon promotes prostate cancer progression
by inducing STRN4 expression. J Cancer. 10:1833–1845.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
The Human Protein Atlas:Available from:
https://www.proteinatlas.org/ENSG00000090372-STRN4/pathology.
|
